Recommendations on Inpatient Treatment of Patients with COVID-19.

BACKGROUND Since identification of the first cases in December 2019, COVID-19, caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has spread across the world, giving rise to a global pandemic. METHODS A literature search was carried out in PubMed, using search terms defined by the authors. Questions important for the management of patients with COVID-19 were identified and discussed, and recommendations or statements on these topics were formulated in a structured consensus process. RESULTS Determination of the indication for the admission of COVID-19 patients to the hospital should involve consideration of age, comorbidities, respiratory rate, and oxygen saturation. Every patient admitted without a recent PCR test should be tested immediately. It is recommended that any COVID-19 patient with hypoxemia (SpO2 <90%) despite being given oxygen, dyspnea, or a high respiratory rate be admitted to intensive care. In the case of hypoxemic respiratory insufficiency, an attempt at treatment with high-flow oxygen or non-invasive ventilation is suggested, while patients with severe hypoxemia/high respiratory rate should undergo intubation and invasive ventilation. In the presence of additional risk factors (such as obesity, known thrombophilia, intensive care treatment, or elevated D-dimers), intensified prophylaxis against thromboembolism may be indicated. Treatment with dexamethasone decreases the mortality among patients with severe or critical COVID-19. The important personal protection measures are attention to hygiene and the correct wearing of personal protective equipment. CONCLUSION The principal treatment measures are maintenance of adequate oxygenation, pharmacological prevention of thrombosis, and, in severe cases, administration of dexamethasone.

[1]  D. Follmann,et al.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.

[2]  Arthur S Slutsky,et al.  The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline , 2020, Intensive Care Medicine.

[3]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[4]  J. Nattermann,et al.  First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)” , 2020, Infection.

[5]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[6]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[7]  Arthur S Slutsky,et al.  Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study , 2020, The Lancet Respiratory Medicine.

[8]  M. Hauptmann,et al.  Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study , 2020, Clinical Microbiology and Infection.

[9]  A. J. Agulló,et al.  Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS , 2020, Intensive Care Medicine.

[10]  G. Michels,et al.  Entscheidungen über die Zuteilung intensivmedizinischer Ressourcen im Kontext der COVID-19-Pandemie , 2020, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[11]  R. Busse,et al.  Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.

[12]  D. MacFadden,et al.  Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis , 2020, Clinical Microbiology and Infection.

[13]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[14]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[15]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[16]  Chaofei Han,et al.  Procalcitonin levels in COVID-19 patients , 2020, International Journal of Antimicrobial Agents.

[17]  N. Patel Pediatric COVID-19: Systematic review of the literature , 2020, American Journal of Otolaryngology.

[18]  J. Oldenburg,et al.  Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis , 2020, Hämostaseologie.

[19]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[20]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[21]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[22]  O. Moerer,et al.  COVID-19-associated nephritis: early warning for disease severity and complications? , 2020, The Lancet.

[23]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[24]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[25]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[26]  T. Cook,et al.  Consensus guidelines for managing the airway in patients with COVID‐19 , 2020, Anaesthesia.

[27]  T. Welte,et al.  [Recommendations for critically ill patients with COVID-19]. , 2020, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[28]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[29]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[30]  Guillermo J. Lagos-Grisales,et al.  Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.

[31]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[32]  Sujata,et al.  A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients in New York City , 2020 .

[33]  I. Hickie,et al.  Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study , 2006, BMJ : British Medical Journal.